BACKGROUND. The subacute demyelinating polyneuropathy known as Guillain-Barre syndrome improves more rapidly with plasma exchange than with supportive care alone. We conducted a multicenter trial to determine whether intravenous immune globulin is as effective as the more complicated treatment with plasma exchange. METHODS. To enter the study, patients had to have had Guillain-Barre syndrome for less than two weeks and had to be unable to walk independently. They were randomly assigned to receive either five plasma exchanges (each of 200 to 250 ml per kilogram of body weight) or five doses of a preparation of intravenous immune globulin (0.4 g per kilogram per day). The predefined outcome measure was improvement at four weeks by at least one grade on a seven-point scale of motor function. RESULTS. After 150 patients had been treated, strength had improved by one grade or more in 34 percent of those treated with plasma exchange, as compared with 53 percent of those treated with immune globulin (difference, 19 percent; 95 percent confidence interval, 3 percent to 34 percent; P = 0.024). The median time to improvement by one grade was 41 days with plasma exchange and 27 days with immune globulin therapy (P = 0.05). The immune globulin group had significantly fewer complications and less need for artificial ventilation. CONCLUSIONS. In the acute Guillain-Barre syndrome, treatment with intravenous immune globulin is at least as effective as plasma exchange and may be superior.
Source Information
Department of Neurology, Academic Hospital Rotterdam, The Netherlands.
This article has been cited by other articles:
Huberle, A., Beyeen, A. D., Ockinger, J., Ayturan, M., Jagodic, M., de Graaf, K. L., Fissolo, N., Marta, M., Olofsson, P., Hultqvist, M., Holmdahl, R., Olsson, T., Weissert, R.
(2009). Advanced Intercross Line Mapping Suggests That Ncf1 (Ean6) Regulates Severity in an Animal Model of Guillain-Barre Syndrome. J. Immunol.
182: 4432-4438
[Abstract][Full Text]
Stangel, M.
(2008). Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins. Therapeutic Advances in Neurological Disorders
1: 115-124
[Abstract]
Lehmann, H. C., Hartung, H.-P.
(2008). Complementing the therapeutic armamentarium for Miller Fisher Syndrome and related immune neuropathies. Brain
131: 1168-1170
[Full Text]
Alshekhlee, A., Hussain, Z., Sultan, B., Katirji, B.
(2008). Guillain-Barre syndrome: Incidence and mortality rates in US hospitals. Neurology
70: 1608-1613
[Abstract][Full Text]
Hughes, R. A. C., Swan, A. V., Raphael, J.-C., Annane, D., van Koningsveld, R., van Doorn, P. A.
(2007). Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain
130: 2245-2257
[Abstract][Full Text]
Gurcan, H. M, Ahmed, A R.
(2007). Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders. The Annals of Pharmacotherapy
41: 812-823
[Abstract][Full Text]
Mori, M., Kuwabara, S., Fukutake, T., Hattori, T.
(2007). Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology
68: 1144-1146
[Abstract][Full Text]
Baranwal, A. K., Ravi, R. N.M., Singh, R.
(2006). Exchange Transfusion: A Low-Cost Alternative for Severe Childhood Guillain-Barre Syndrome. J Child Neurol
21: 960-965
[Abstract]
Geleijns, K., Roos, A., Houwing-Duistermaat, J. J., van Rijs, W., Tio-Gillen, A. P., Laman, J. D., van Doorn, P. A., Jacobs, B. C.
(2006). Mannose-Binding Lectin Contributes to the Severity of Guillain-Barre Syndrome. J. Immunol.
177: 4211-4217
[Abstract][Full Text]
Lehmann, H. C., Hartung, H.-P., Hetzel, G. R., Stuve, O., Kieseier, B. C.
(2006). Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders.. Arch Neurol
63: 1066-1071
[Abstract][Full Text]
Schmidt-Ott, R., Schmidt, H., Feldmann, S., Brass, F., Krone, B., Gross, U.
(2006). Improved Serological Diagnosis Stresses the Major Role of Campylobacter jejuni in Triggering Guillain-Barre Syndrome.. CVI
13: 779-783
[Abstract][Full Text]
Radstake, T R D J, Nabbe, K C A M, Wenink, M H, Roelofs, M F, Oosterlaar, A, van Lieshout, A W T, Barrera, P, van Lent, P L E M, van den Berg, W B
(2005). Dendritic cells from patients with rheumatoid arthritis lack the interleukin 13 mediated increase of Fc{gamma}RII expression, which has clear functional consequences. Ann Rheum Dis
64: 1737-1743
[Abstract][Full Text]
Radstake, T R D J, van Lieshout, A W T, van Riel, P L C M, van den Berg, W B, Adema, G J
(2005). Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis. Ann Rheum Dis
64: 1532-1538
[Abstract][Full Text]
Greenhouse, J. B, Seltman, H.
(2005). Using prior distributions to synthesize historical evidence: comments on the Goodman-Sladky case study of IVIg in Guillain-Barre syndrome. Clin Trials
2: 311-318
[Abstract]
Natarajan, N., Weinstein, R.
(2005). Therapeutic Apheresis in Neurology Critical Care. J Intensive Care Med
20: 212-225
[Abstract]
Korinthenberg, R., Schessl, J., Kirschner, J., Monting, J. S.
(2005). Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial. Pediatrics
116: 8-14
[Abstract][Full Text]
Abe, J., Jibiki, T., Noma, S., Nakajima, T., Saito, H., Terai, M.
(2005). Gene Expression Profiling of the Effect of High-Dose Intravenous Ig in Patients with Kawasaki Disease. J. Immunol.
174: 5837-5845
[Abstract][Full Text]
Linenberger, M. L., Price, T. H.
(2005). Use of Cellular and Plasma Apheresis in the Critically Ill Patient: Part II: Clinical Indications and Applications. J Intensive Care Med
20: 88-103
[Abstract]
Geleijns, K., Schreuder, G. M.Th., Jacobs, B. C., Sintnicolaas, K., van Koningsveld, R., Meulstee, J., Laman, J. D., van Doorn, P. A.
(2005). HLA class II alleles are not a general susceptibility factor in Guillain-Barre syndrome. Neurology
64: 44-49
[Abstract][Full Text]
Soelberg Sorensen, P., Haas, J., Sellebjerg, F., Olsson, T., Ravnborg, M., the TARIMS Study Group,
(2004). IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology
63: 2028-2033
[Abstract][Full Text]
Nishimoto, Y., Koga, M., Kamijo, M., Hirata, K., Yuki, N.
(2004). Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration. Neurology
62: 1939-1944
[Abstract][Full Text]
Horn, H C, Grau, K, Junker, P
(2004). IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome. Lupus
13: 478-480
[Abstract]
Dalakas, M. C.
(2004). Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA
291: 2367-2375
[Abstract][Full Text]
Koul, R., Chacko, A., Ahmed, R., Varghese, T., Javed, H., Al-Lamki, Z.
(2003). Ten-Year Prospective Study (Clinical Spectrum) of Childhood Guillain-Barre Syndrome in the Arabian Peninsula: Comparison of Outcome in Patients in the Pre-- and Post--Intravenous Immunoglobulin Eras. J Child Neurol
18: 767-771
[Abstract]
Odaka, M., Yuki, N., Yamada, M., Koga, M., Takemi, T., Hirata, K., Kuwabara, S.
(2003). Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain
126: 2279-2290
[Abstract][Full Text]
Jacobs, B. C., O'Hanlon, G. M., Bullens, R. W. M., Veitch, J., Plomp, J. J., Willison, H. J.
(2003). Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain
126: 2220-2234
[Abstract][Full Text]
Hughes, R.A.C., Wijdicks, E.F.M., Barohn, R., Benson, E., Cornblath, D.R., Hahn, A. F., Meythaler, J.M., Miller, R.G., Sladky, J.T., Stevens, J.C.
(2003). Practice parameter: Immunotherapy for Guillain-Barre syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology
61: 736-740
[Abstract][Full Text]
Hughes, R. A C
(2003). Treating nerves: from anecdote to systematic review. JRSM
96: 432-435
[Full Text]
Wanschitz, J., Maier, H., Lassmann, H., Budka, H., Berger, T.
(2003). Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barre syndrome. Brain
126: 2034-2042
[Abstract][Full Text]
Hiraga, A., Mori, M., Ogawara, K., Hattori, T., Kuwabara, S.
(2003). Differences in patterns of progression in demyelinating and axonal Guillain-Barre syndromes. Neurology
61: 471-474
[Abstract][Full Text]
Song, S., Crow, A. R., Freedman, J., Lazarus, A. H.
(2003). Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood
101: 3708-3713
[Abstract][Full Text]
Bayry, J., Lacroix-Desmazes, S., Carbonneil, C., Misra, N., Donkova, V., Pashov, A., Chevailler, A., Mouthon, L., Weill, B., Bruneval, P., Kazatchkine, M. D., Kaveri, S. V.
(2003). Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood
101: 758-765
[Abstract][Full Text]
Brannagan, T. H. III
(2002). Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology
59: S33-40
[Abstract][Full Text]
Willison, H. J., Yuki, N.
(2002). Peripheral neuropathies and anti-glycolipid antibodies. Brain
125: 2591-2625
[Abstract][Full Text]
Merkies, I S J, Schmitz, P I M, van der Meche, F G A, Samijn, J P A, van Doorn, P A
(2002). Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J. Neurol. Neurosurg. Psychiatry
72: 596-601
[Abstract][Full Text]
Mori, M, Kuwabara, S, Fukutake, T, Hattori, T
(2002). Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases. J. Neurol. Neurosurg. Psychiatry
72: 680-680
[Full Text]
Sharma, K. R., Cross, J., Ayyar, D. R., Martinez-Arizala, A., Bradley, W. G.
(2002). Diabetic Demyelinating Polyneuropathy Responsive to Intravenous Immunoglobulin Therapy. Arch Neurol
59: 751-757
[Abstract][Full Text]
Wiles, C M, Brown, P, Chapel, H, Guerrini, R, Hughes, R A C, Martin, T D, McCrone, P, Newsom-Davis, J, Palace, J, Rees, J H, Rose, M R, Scolding, N, Webster, A D B
(2002). Intravenous immunoglobulin in neurological disease: a specialist review. J. Neurol. Neurosurg. Psychiatry
72: 440-448
[Abstract][Full Text]
Mori, K., Hattori, N., Sugiura, M., Koike, H., Misu, K., Ichimura, M., Hirayama, M., Sobue, G.
(2002). Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology
58: 979-982
[Abstract][Full Text]
Van Koningsveld, R., Schmitz, P.I.M., Ang, C.W., Groen, J., Osterhaus, A.D.M.E., Van der Meche, F.G.A., Van Doorn, P. A.
(2002). Infections and course of disease in mild forms of Guillain-Barre syndrome. Neurology
58: 610-614
[Abstract][Full Text]
Kishimoto, C., Takada, H., Kawamata, H., Umatake, M., Ochiai, H.
(2001). Immunoglobulin Treatment Prevents Congestive Heart Failure in Murine Encephalomyocarditis Viral Myocarditis Associated with Reduction of Inflammatory Cytokines. J. Pharmacol. Exp. Ther.
299: 645-651
[Abstract][Full Text]
Feasby, T. E., Hartung, H.-P.
(2001). Drain the roots: A new treatment for Guillain-Barre syndrome?. Neurology
57: 753-754
[Full Text]
Wollinsky, K.H., Hulser, P.-J., Brinkmeier, H., Aulkemeyer, P., Bossenecker, W., Huber-Hartmann, K.-H., Rohrbach, P., Schreiber, H., Weber, F., Kron, M., Buchele, G., Mehrkens, H.-H., Ludolph, A.C., Rudel, R.
(2001). CSF filtration is an effective treatment of Guillain-Barre syndrome: A randomized clinical trial. Neurology
57: 774-780
[Abstract][Full Text]
Kazatchkine, M. D., Kaveri, S. V.
(2001). Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin. NEJM
345: 747-755
[Full Text]
Raphael, J-C, Chevret, S, Harboun, M, Jars-Guincestre, M-C.
(2001). Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J. Neurol. Neurosurg. Psychiatry
71: 235-238
[Abstract][Full Text]
PROVENCIO, J. J., BLECK, T. P., CONNORS, A. F. Jr.
(2001). Critical Care Neurology. Am. J. Respir. Crit. Care Med.
164: 341-345
[Full Text]
Bradshaw, D. Y., Jones, H. R.
(2001). Pseudomeningoencephalitic Presentation of Pediatric Guillain-Barre Syndrome. J Child Neurol
16: 505-508
[Abstract]
Gordon, P. H., Wilbourn, A. J.
(2001). Early Electrodiagnostic Findings in Guillain-Barre Syndrome. Arch Neurol
58: 913-917
[Abstract][Full Text]
Koga, M, Ang, C W, Yuki, N, Jacobs, B C, Herbrink, P, van der Meche, F G A, Hirata, K, van Doorn, P A
(2001). Comparative study of preceding Campylobacter jejuni infection in Guillain-Barre syndrome in Japan and The Netherlands. J. Neurol. Neurosurg. Psychiatry
70: 693-695
[Abstract][Full Text]
Van Koningsveld, R., Van Doorn, P.A., Schmitz, P.I.M., Van der Meche, F.G.A.
(2001). Changes in referral pattern and its effect on outcome in patients with Guillain-Barre syndrome. Neurology
56: 564-566
[Abstract][Full Text]
Samuelsson, A., Towers, T. L., Ravetch, J. V.
(2001). Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor. Science
291: 484-486
[Abstract][Full Text]
Prendergast, M. M., Moran, A. P.
(2000). Review: Lipopolysaccharides in the development of the Guillain-Barre syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies. Innate Immunity
6: 341-359
[Abstract]
Fletcher, D. D., Lawn, N. D., Wolter, T. D., Wijdicks, E. F. M.
(2000). Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation. Neurology
54: 2311-2315
[Abstract][Full Text]
van der Pol, W.-L., van den Berg, L. H., Scheepers, R. H. M., van der Bom, J. G., van Doorn, P. A., van Koningsveld, R., van den Broek, M. C. L., Wokke, J. H. J., van de Winkel, J. G. J.
(2000). IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barre syndrome. Neurology
54: 1661-1665
[Abstract][Full Text]
DE LETTER, M A C J, VISSER, L., DE LETTER, M A C J, ANG, W, VAN DER MECHE, F G A, ANG, W, SAVELKOUL;, H F J, YUKI, N.
(2000). Distinctions between critical illness polyneuropathy and axonal Guillain- Barre syndrome. J. Neurol. Neurosurg. Psychiatry
68: 397-398
[Full Text]
Asbury, A. K.
(2000). New Concepts of Guillain-Barre Syndrome. J Child Neurol
15: 183-191
[Abstract]
Merkies, I. S. J., Schmitz, P. I. M., van der Meche, F. G. A., van Doorn, P. A.
(2000). Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Neurology
54: 943-949
[Abstract][Full Text]
Takeuchi, H., Misu, K., Hattori, N., Nagamatsu, M., Sobue, G.
(2000). Immunoglobulin therapy for idiopathic chronic sensory ataxic neuropathy. Neurology
54: 1008-1010
[Full Text]
Van Koningsveld, R., Van Doorn, P. A., Schmitz, P. I. M., Ang, C. W., Van der Meche, F. G. A.
(2000). Mild forms of Guillain-Barre syndrome in an epidemiologic survey in the Netherlands. Neurology
54: 620-620
[Abstract][Full Text]
Kaida, K., Kusunoki, S., Kamakura, K., Motoyoshi, K., Kanazawa, I.
(2000). Guillain-Barre syndrome with antibody to a ganglioside, N-acetylgalactosaminyl GD1a. Brain
123: 116-124
[Abstract][Full Text]
Ang, C. W., Yuki, N., Jacobs, B. C., Koga, M., Van Doorn, P. A., Schmitz, P. I. M., Van Der Meche, F. G. A.
(1999). Rapidly progressive, predominantly motor Guillain-Barre syndrome with anti-GalNAc-GD1a antibodies. Neurology
53: 2122-2122
[Abstract][Full Text]
Logina, I., Donaghy, M.
(1999). Diphtheritic polyneuropathy: a clinical study and comparison with Guillain-Barre syndrome. J. Neurol. Neurosurg. Psychiatry
67: 433-438
[Abstract][Full Text]
Clark, W. F., Rock, G. A., Buskard, N., Shumak, K. H., LeBlond, P., Anderson, D., Sutton, D. M., for the Canadian Apheresis Group*,
(1999). Therapeutic Plasma Exchange: An Update from the Canadian Apheresis Group. ANN INTERN MED
131: 453-462
[Abstract][Full Text]
Shoenfeld, Y., Fishman, P.
(1999). Gamma-globulin inhibits tumor spread in mice. Int Immunol
11: 1247-1252
[Abstract][Full Text]
Sorensen, P. S.
(1999). Intravenous Immunoglobulin Treatment in Neurologic Disorders: Yes. Arch Neurol
56: 1025-1027
[Full Text]
Karussis, D., Abramsky, O.
(1999). Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?: No. Arch Neurol
56: 1028-1032
[Full Text]
Visser, L. H., Schmitz, P. I. M., Meulstee, J., van Doorn, P. A., van der Meche, F. G. A.
(1999). Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange. Neurology
53: 598-598
[Abstract][Full Text]
Assa, A., Watemberg, N., Bujanover, Y., Lerman-Sagie, T.
(1999). Demyelinative Brainstem Encephalitis Responsive to Intravenous Immunoglobulin Therapy. Pediatrics
104: 301-303
[Abstract][Full Text]
Bernsen, R. A. J. A. M., de Jager, A. E. J., Schmitz, P. I. M., van der Meche, F. G. A.
(1999). Residual physical outcome and daily living 3 to 6 years after Guillain-Barre syndrome. Neurology
53: 409-409
[Abstract][Full Text]
Koga, M., Yuki, N., Hirata, K.
(1999). Antiganglioside antibody in patients with Guillain-Barre syndrome who show bulbar palsy as an initial symptom. J. Neurol. Neurosurg. Psychiatry
66: 513-516
[Abstract][Full Text]
Lawn, N. D., Wijdicks, E. F. M.
(1999). Fatal Guillain-Barre syndrome. Neurology
52: 635-635
[Abstract][Full Text]
North, K.
(1999). NEW PERSPECTIVES IN PEDIATRIC NEUROMUSCULAR DISORDERS Hotel Intercontinental Sydney, Sydney, Australia, August 28, 1998. J Child Neurol
14: 26-57
Ismail, E. A. R., Shabani, I. S., Badawi, M., Sanaa, H., Madi, S., Al-Tawari, A., Nadi, H., Zaki, M., Al-saleh, Q.
(1998). An Epidemiologic, Clinical, and Therapeutic Study of Childhood Guillain-Barre Syndrome in Kuwait: Is It Related to the Oral Polio Vaccine?. J Child Neurol
13: 488-492
[Abstract]
Xu, C., Poirier, B., Duong Van Huyen, J.-P., Lucchiari, N., Michel, O., Chevalier, J., Kaveri, S.
(1998). Modulation of Endothelial Cell Function by Normal Polyspecific Human Intravenous Immunoglobulins : A Possible Mechanism of Action in Vascular Diseases. Am. J. Pathol.
153: 1257-1266
[Abstract][Full Text]
Prendergast, M. M., Lastovica, A. J., Moran, A. P.
(1998). Lipopolysaccharides from Campylobacter jejuni O:41 Strains Associated with Guillain-Barre Syndrome Exhibit Mimicry of GM1 Ganglioside. Infect. Immun.
66: 3649-3655
[Abstract][Full Text]
Nicoletti, F., Nicoletti, A., Giuffrida, S., Di Marco, R., Meroni, P., Bendtzen, K., Lunetta, M.
(1998). Sodium fusidate in Guillain-Barre syndrome: a case report. J. Neurol. Neurosurg. Psychiatry
65: 266-268
[Abstract][Full Text]
Nachamkin, I., Allos, B. M., Ho, T.
(1998). Campylobacter Species and Guillain-Barre Syndrome. Clin. Microbiol. Rev.
11: 555-567
[Abstract][Full Text]
Asakura, K, Rodriguez, M
(1998). A unique population of circulating autoantibodies promotes central nervous system remyelination. Mult Scler
4: 217-221
[Abstract]
Wong, B. L. Y., Glauser, T. A.
(1998). Single High-Dose Intravenous Immunoglobulin for Treatment of Pediatric Guillain-Barre Syndrome. J Child Neurol
13: 146-146
Visser, L., van der Meche, F., Meulstee, J, van Doorn, P., the Dutch Guillain-Barre study group,
(1998). Risk factors for treatment related clinical fluctuations in Guillain-Barre syndrome. J. Neurol. Neurosurg. Psychiatry
64: 242-244
[Abstract][Full Text]
Rees, J H, Thompson, R D, Smeeton, N C, Hughes, R A C
(1998). Epidemiological study of Guillain-Barre syndrome in south east England. J. Neurol. Neurosurg. Psychiatry
64: 74-77
[Abstract][Full Text]
Francis, G. S, Freedman, M. S, Antel, J. P
(1997). Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Mult Scler
3: 370-376
[Abstract]
Mariette, X., Chastang, C., Louboutin, J.-P., Leger, J.-M., Clavelou, P., Brouet, J.-C.
(1997). A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. J. Neurol. Neurosurg. Psychiatry
63: 28-34
[Abstract][Full Text]
Sewell, W A C, Brennan, V M, Donaghy, M, Chapel, H M
(1997). The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies. J. Neurol. Neurosurg. Psychiatry
63: 106-109
[Abstract][Full Text]
Sandrock, A. W., Cros, D. P., Louis, D. N.
(1997). Case 11-1997- A 51-year-old Man with Chronic Obstructive Pulmonary Disease and Generalized Muscle Weakness. NEJM
336: 1079-1088
[Full Text]
Hughes, R.A.C., Gabriel, C.M., Gregson, N.A., Smith, K.J.
(1997). Treatment of inflammatory neuropathy. Mult Scler
3: 88-92
[Abstract]
van Schaik, I., Vermeulen, M., Brand, A.
(1997). Immunomodulation and remyelination: two aspects of human polyclonal immunoglobulin treatment in immune mediated neuropathies?. Mult Scler
3: 98-104
[Abstract]
Kaveri, S., Prasad, N., Vassilev, T., Hurez, V., Pashov, A., Lacroix-Desmazes, S., Kazatchkine, M.
(1997). Modulation of autoimmune responses by intravenous immunoglobulin (IVIg). Mult Scler
3: 121-128
[Abstract]
Fazekas, F., Deisenhammer, F., Strasser-Fuchs, S., Nahler, G., Mamoli, B. for the Au
(1997). Treatment effects of monthly intravenous immunoglobulin on patients with relapsing - remitting Multiple Sclerosis: Further analyses of the Austrian immunoglobulin in MS Study. Mult Scler
3: 137-141
[Abstract]
Moran, A.P., Appelmelk, B.J., Aspinall, G.O.
(1996). Review: Molecular mimicry of host structures by lipopolysaccharides of Campylobacter and Helicobacter spp.: implications in pathogenesis. Innate Immunity
3: 521-531
[Abstract]
Jackson, A. H., Baquis, G. D., Shah, B. L.
(1996). Congenital Guillain-Barre Syndrome. J Child Neurol
11: 407-410
Hughes, R A C
(1996). Intravenous IgG in Guillain-Barre syndrome. BMJ
313: 376-377
[Full Text]
Jacobs, B. C., Schmitz, P. I.M., van der Meche, F. G.A., Rees, J. H.
(1996). Campylobacter jejuni Infection and Treatment for Guillain-Barre Syndrome. NEJM
335: 208-209
[Full Text]
Aguado, J. M., Ramos, J. T., Lumbreras, C., Rees, J. H.
(1996). Campylobacter jejuni Infection and Guillain-Barre Syndrome. NEJM
334: 802-802
[Full Text]
Delgado, M. R.
(1996). Guillain-Barre Syndrome: A Pediatric Challenge. J Child Neurol
11: 1-3
Jones, H. R. JR
(1996). Topical Review: Childhood Guillain-Barre Syndrome: Clinical Presentation, Diagnosis, and Therapy. J Child Neurol
11: 4-12
[Abstract]
Schwerer, B., Neisser, A., Polt, R.J., Bernheimer, H., Moran, A.P.
(1995). Antibody cross-reactivities between gangliosides and lipopolysaccharides of Campylobacter jejuni serotypes associated with Guillain-Barre syndrome. Innate Immunity
2: 395-403
[Abstract]
Previous
